HUMANIZED AND CHIMERIC ANTI-PROPERDIN ANTIBODIES

• US 20140186348A1
• Filed: 03/03/2014
• Published: 07/03/2014
• Est. Priority Date: 03/10/2010
• Status: Abandoned Application

• Current Assignee: Novelmed Therapeutics, Inc.
• Original Assignee: Novelmed Therapeutics, Inc.
• Inventors: Bansal, Rekha
• Application Number:
  US14/195,458
• Publication Number:
  US 20140186348A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3CDRS in SEQ ID NO: 9.

Claims

1. A method of inhibiting alternative complement pathway activation in a mammal, the method comprising:

administering to the mammal an isolated anti-properdin antibody or antigen binding portion thereof that specifically binds to properdin and inhibits alternative complement pathway activation, wherein the isolated anti-properdin antibody or antigen binding portion thereof (i) comprises at least one CDR having at least 80% sequence identity to SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, or (ii) competitively inhibits binding of an isolated anti-properdin antibody or antigen binding portion thereof, which comprises at least one CDR having at least 80% sequence identity to SEQ ID;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, to properdin.

2. The method of claim 1, wherein the isolated anti-properdin antibody or antigen binding portion thereof (i) comprises at least two CDRs having at least 80% sequence identity to at least two of SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, or (ii) competitively inhibits binding of an isolated anti-properdin antibody or antigen binding portion thereof, which comprises at least two CDRs having at least 80% sequence identity to at least two of SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, to properdin.

3. The method of claim 1, wherein the isolated anti-properdin antibody or antigen binding portion thereof (i) comprises at least three CDRs having at least 80% sequence identity to at least three of SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, or (ii) competitively inhibits binding of an isolated anti-properdin antibody or antigen binding portion thereof, which comprises at least three CDRs having at least 80% sequence identity to at least three of SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, to properdin.

4. The method of claim 1, wherein the isolated anti-properdin antibody or antigen binding portion thereof (i) comprises at least four CDRs having at least 80% sequence identity to at least four of SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, or (ii) competitively inhibits binding of an isolated anti-properdin antibody or antigen binding portion thereof, which comprises at least four CDRs having at least 80% sequence identity to at least four of SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, to properdin.

5. The method of claim 1, wherein the isolated anti-properdin antibody or antigen binding portion thereof (i) comprises at least five CDRs having at least 80% sequence identity to at least five of SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, or (ii) competitively inhibits binding of an isolated anti-properdin antibody or antigen binding portion thereof, which comprises at least five CDRs having at least 80% sequence identity to at least five of SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, or SEQ ID NO;

16, to properdin.

6. The method of claim 1, wherein the isolated anti-properdin antibody or antigen binding portion thereof (i) comprises six CDRs having at least 80% sequence identity to SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, or (ii) competitively inhibits binding of an isolated anti-properdin antibody or antigen binding portion thereof, which comprises six CDRs having at least 80% sequence identity to SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, to properdin.

7. The method of claim 1, wherein the isolated anti-properdin antibody or antigen binding portion thereof (i) comprises six CDRs having at least 90% sequence identity to SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, or (ii) competitively inhibits binding of an isolated anti-properdin antibody or antigen binding portion thereof, which comprises six CDRs having at least 90% sequence identity to SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, to properdin.

8. The method of claim 1, wherein the mammal has a disease or disorder in which activation of the alternative complement pathway plays a role, and wherein the steps of administering the antibody or antigen binding fragment thereof treats or prevents the disease or disorder.

9. The method of claim 8, wherein the disease or disorder is inflammatory in nature, or which originates in an inflammatory condition.

10. The method of claim 8, wherein the disease or disorder is autoimmune in nature, or which originates in an autoimmune condition.

11. The method of claim 10, wherein the autoimmune disease or disorder is a manifestation of one of the group consisting of;

systemic lupus erythematosus, myasthenia gravis, arthritic condition, Alzheimer'"'"'s disease and multiple sclerosis.

12. The method of claim 8, wherein the disease or disorder is an arthritic condition or originates in an arthritic condition.

13. The method of claim 12, wherein the disease or disorder is a manifestation of an arthritic condition selected from the group consisting of rheumatoid arthritis, osteo-arthritis, and juvenile arthritis.

14. The method of claim 8, wherein the disease or disorder is an ocular condition or originates in an ocular condition.

15. The method of claim 14, wherein the ocular disease or ocular disorder is a manifestation of one selected from the group consisting of:

diabetic retinopathy, histoplasmosis of the eye, age-related macular degeneration, diabetic retinopathy, choroidal neo-vascularization (CNV), retinal neovascularization, uveitis, diabetic macular edema, pathological myopia, von Hippel-Lindau disease, Central Retinal Vein Occlusion (CRVO), North Carolina macular dystrophy, Sorsby'"'"'s fundus dystrophy, Stargardt'"'"'s disease, pattern dystrophy, Best disease, dominant drusen, malattia leventinese, retinal fibrosis, retinal detachment, chorioretinal degeneration, retinal degeneration, photoreceptor degeneration, RPE degeneration, mucopolysaccharidoses, rod-cone dystrophies, cone-rod dystrophy, cone degeneration, endophthalmitis, Polypoidal Choroidal Vasculopathy, hypertensive retinopathy, sickle cell retinopathy, Purtscher'"'"'s retinopathy, peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, and ocular neoplasm.

16. The method of claim 15, wherein the ocular disease or disorder is a manifestation of age-related macular degeneration, and which is intermediate dry AMD or geographic atrophy.

17. The method of claim 8, wherein the disease or disorder is an asthmatic disorder or airway inflammation disorder, or which originates in an asthmatic disorder or airway inflammation disorder.

18. The method of claim 17, wherein the disease or disorder is an airway inflammation disorder is a manifestation of one of the group comprising of;

asthma, chronic obstructive pulmonary disease (“

COPD”

), allergic broncho-pulmonary aspergillosis, hypersensitivity pneumonia, eosinophilic pneumonia, emphysema, bronchitis, allergic bronchitis bronchiecstasis, cyctic fibrosis, tuberculosis, hypersensitivity pneumonitis, occupational asthma, sarcoid, reactive airway disease syndrome, interstitial lung disease, hyper-eosinophilic syndrome, rhinitis, sinusitis, exercise-induced asthma, pollution-induced asthma, cough variant asthma, parasitic lung disease, respiratory syncytial virus (“

RSV”

) infection, parainfluenza virus (“

PIV”

) infection, rhinovirus (“

RV”

) infection, and adenovirus infection.

19. A method of inhibiting alternative pathway activation in a mammal that has, or is at risk of developing, a condition or disease in which the alternative pathway contributes to disease pathology, or exacerbates at least one symptom caused by the condition or disease, the method comprising:

administering to the mammal an isolated anti-properdin antibody or antigen binding portion thereof that specifically binds to properdin and inhibits alternative complement pathway activation, wherein the isolated anti-properdin antibody or antigen binding portion thereof competitively inhibits binding of an isolated anti-properdin antibody or antigen binding portion thereof, which comprises a heavy chain variable domain which contains the sequences of the three CDRs with the sequences of SEQ ID NOs;

6, 7 and 8, and a light chain variable domain which contains the sequences of the three CDRs with the sequences of SEQ ID NOs;

14, 15 and 16 to properdin.

20. The method of claim 19, further comprising administering a chimeric or humanized anti-properdin antibody or antigen binding portion thereof that is pegylated and/or conjugated with a synthetic chemical entity.

21. The method of claim 20 wherein isolated antibody antigen binding portion thereof does not include heavy chain variable domain CDRs having SEQ ID NOs:

6, 7 and 8, and light chain variable domain CDRs having SEQ ID NOs;

14, 15 and 16.

22. The method of claim 19, wherein the isolated antibody antigen binding portion thereof is selected from the group consisting of a mouse, chimeric, human, and humanized antibody or antigen binding portion thereof.

23. The method of claim 19 wherein competitive inhibition of the antibody or antigen binding portion thereof is about 100%.

24. The method of claim 19 wherein competitive inhibition of the antibody or antigen binding portion thereof is at least about 90%.

25. The method of claim 19 wherein competitive inhibition of the antibody or antigen binding portion thereof is at least about 70%.

26. The method of claim 19 wherein competitive inhibition of the antibody or antigen binding portion thereof is at least about 50%.

27. The method of claim 19 wherein competitive inhibition of the antibody or antigen binding portion thereof is at least about 30%.

28. A method of inhibiting alternative complement pathway activation in a mammal, the method comprising:

administering to the mammal an agent that specifically binds to properdin and competes with an anti-properdin antibody or antigen binding portion, which comprises CDRs having at least 90% sequence identity to SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, for binding to properdin.

29. The method of claim 28, wherein the agent is an isolated anti-properdin antibody or antigen binding portion thereof.

30. The method of claim 29 wherein isolated antibody or antigen binding portion thereof does not include heavy chain variable domain CDRs having SEQ ID NOs:

6, 7 and 8, and light chain variable domain CDRs having SEQ ID NOs;

14, 15 and 16.

31. The method of claim 29, wherein the isolated antibody or antigen binding portion thereof is selected from the group consisting of a mouse, chimeric, human, and humanized antibody or antigen binding portion thereof.

32. The method of claim 29, wherein the antibody or antigen bind portion thereof competitively inhibits binding of the anti-properdin antibody or antigen binding portion, which comprises CDRs having at least 90% sequence identity to SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, at least about 30%.

33. The method of claim 29, wherein the antibody or antigen bind portion thereof competitively inhibits binding of the anti-properdin antibody or antigen binding portion, which comprises CDRs having at least 90% sequence identity to SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, at least about 50%.

34. The method of claim 29 wherein the antibody or antigen bind portion thereof competitively inhibits binding of the anti-properdin antibody or antigen binding portion, which comprises CDRs having at least 90% sequence identity to SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, at least about 70%.

35. The method of claim 29 wherein the antibody or antigen bind portion thereof competitively inhibits binding of the anti-properdin antibody or antigen binding portion, which comprises CDRs having at least 80% sequence identity to SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

14, SEQ ID NO;

15, and SEQ ID NO;

16, at least about 90%.